A remedy for weight loss, drugs for diabetes associated with vision problems in small research
Popular drugs for diabetes and weight loss could have an unexpected side effect.
The receptor agonists on similar glucagon, agonists GLP-1), which are used to treat diabetes and/or obesity of type 2, are associated with vision problems in a small study at British Columbia University.
Some common Glp-1 drug Include ground and wegovy, containing semaglutide as an active ingredient, and mounjaro and Zepbound, containing thyrzepatide.
Weight loss can be helped by drinking this, the study suggests
In the study, nine patients using GLP-1 developed “ophthalmic complications” according to researchers. The average age of the patient was 57.4 years, according to the study.
Glucagon similar to peptide 1 (GLP-1) receptor agonists, used to treat diabetes and/or obesity of type 2, were associated with vision problems in a small study. (East)
Seven patients had a neurterite front ischemic optical neuropathy (Naion), causing visual loss in one eye.
One patient developed bilateral papitis, which includes swollen optical nerves that can cause impaired vision and the other had a paracentral acute middle maculopathy, leading to a blind place in Mrežnica.
Health benefits of Orempic are still growing, but are the risks?
All patients had a history of type 2 diabetes, hyperlipidemia (high lipids or fat fats), hypertension and/or sleep apnea.
The discoveries were published in Opphthalmology Cave.
“In one of the cases presented, the patient was taking weight loss and did not have a previous history of diabetes (which can also be associated with the condition),” leading author Mahyar Etminan Associate Professor of Medicine at the University of British Columbia told Fox News Digital.
The doctor (which is not in the picture) emphasized that these drugs should only be taken under the custody of the health care worker and that “it is good and consistently monitoring the dose adjustment with the control of the side effects.” (East)
“In the second case, when the drug was stopped and re -introduced, the condition appeared, strengthening the causal relationship.”
Ziyad al-Aly, clinical epidemiologist at Washington University in St. Louis, he was not involved in the studio, but shared his comments on the findings.
“This is a very small study and she was uncontrolled-what means she didn’t involve people who didn’t use GLP-1 drugs,” he told Fox News Digital.
“The story of GLP-1 is still writing-we learn something new about these drugs every day.”
“This makes it impossible to know if registered eye problems are caused by these drugs.”
Still, the doctor noted: “The story of GLP-1 still writes and we learn something new about these drugs every day. The findings in this study need to follow.”
Seven patients in the study developed a neurterite front ischemic optical neuropathy (Naion), causing visual loss in one eye. (East)
Etminan, author of Olovo Study, also acknowledged the restrictions on the study.
“These data were derived from a series of individual cases and were not an epidemiological study,” he noticed. “However, another recent epidemiological study also confirmed the risk increase.”
BMI is a wrong way to measure obesity, the researchers say – here’s what they recommend instead
Al-Aly has called for large, controlled studies-ups by taking people who take the medicine and a control group of people who do not use the drug-for the long-term health effects of these drugs, including eye problems.
“In the meantime, for people who can be at risk of vision problems or who already have vision problems, caution advises,” he added. “People should Discuss with their doctors To determine if GLP-1 is the right cure for them. “
“This is a very small study and she was uncontrolled-what does she mean that she did not involve people who did not use GLP-1 drugs,” a Fox News Digital doctor told Fox News. (East)
Etminan repeated the warning instructions.
“Those who take these diabetes medicines should probably continue to take them for their cardiovascular advantagesBut be aware of the signs of Nation, “he advised.
“Healthy individuals who take them to lose a few pounds for the event might want to take care of the risks more carefully than the benefits of taking these medicines.”
“Most of the side effects seem to be resolved when the medicine stops.”
Dr. Seth Kipnis, Medical Director of Bariatric and Robot Surgery in Hackensack Meridian Jersey Shore Medical Center, noted that there were “rare and unusual side effects from this class of medication”, but believes The vision changes It seems more associated with rapid changes in blood sugar caused by drugs than on the drugs themselves.
Click here to get the Fox News app
“We have encouraged all patients who are on these types of drugs to report all unusual symptoms Prescribing a doctor“Kipnis, who was also not involved in the research, he told Fox News Digital.
“Most of the side effects seem to be resolved when the medicine stops.”
Click here to sign up for our Health Bulletin
The sculptor emphasized that these drugs should only be taken under the custody of a healthcare professional and that “it is a good and consistent monitoring of doses with the supervision of side effects” critical.
When he was contacted by Fox News Digital, Novo Nordisk (Oskempic and Wegovy manufacturer) made the following statement.
“Those who take these diabetes medicines should probably continue to take them for their cardiovascular benefits, but be aware of the Naion signs,” the doctor advised. (East)
“Naion is a very rare eye disease and is not a harmful reaction of medicines for the placed formulations of the Semaglutide (Omempic®, Rybelsus® and Wegovy®) according to approved labels. After thorough assessment of studies from the University of South, the Denmark and Novo Nordisk Assessment Assessment Assessment, Novo Nordisk thinks is a profile of beneficial risk of semaglutide remains unchanged. “
The company also noticed that the conditions of the eye “are well -known comorbits” for people To live with diabetes.
For more health articles visit www.foxnews.com/health/health
“Any decision on the start of drug treatment should only be made in consultation with a healthcare worker who should make an assessment at the risk of the patient in question, measuring the benefits of treatment with potential risks,” Novi Nordisk added.
